Hospital Infection Control in Hematopoietic Stem Cell Transplant Recipients

Clare A. Dykewicz
Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients contains a section on hospital infection control including evidence-based recommendations regarding ventilation, construction, equipment, plants, play areas and toys, health-care workers, visitors, patient skin and oral care, catheter-related infections, drug-resistant organisms, and specific nosocomial infections. These guidelines are intended to reduce the number and severity of hospital infections in hematopoietic stem cell transplant recipients.

The Centers for Disease Control and Prevention (CDC), the Infectious Diseases Society of America (IDSA), and the American Society for Blood and Marrow Transplantation (ASBMT) sponsored the Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients. This document was drafted in 1997 by a working group of infectious disease and transplant experts, revised extensively from 1997 to 1999, and released for public comment on September 15, 1999, on the CDC website. The final document was published in CDC’s Morbidity and Mortality Weekly Report on October 20, 2000, and in the Biology of Blood and Marrow Transplantation in late 2000. The term hematopoietic stem cell transplant recipients (HSCT) is preferable to “bone marrow transplant recipients” because the new term more accurately describes the current state of transplantation, which may involve harvesting donor cells from peripheral blood, umbilical cord blood, or bone marrow (1).

The document is an evidence-based statement of recommended strategies for preventing opportunistic infections in HSCT recipients. The prevention strategies are rated by the strength of the recommendation and the quality of the evidence supporting it. This rating system was developed by IDSA and the U.S. Public Health Service for use in the guidelines for the prevention of opportunistic infections in persons infected with HIV (2). The rating system allows the importance of each recommendation to be assessed. An A rating indicates strong evidence for efficacy and clinical benefit and an intervention that should always be offered; an intervention with a B rating is supported by moderate evidence and generally should be offered; a C rating indicates an optional intervention because evidence is insufficient to support a recommendation or evidence for efficacy might not outweigh adverse effects; a D rating indicates that moderate evidence for lack of efficacy or adverse outcome supports recommending against the intervention; and an E rating indicates strong evidence that an intervention is contraindi-
determined whether survival of HSCT recipients with aplastic anemia improves when they are treated in rooms with laminar air flow. Therefore, such rooms need not be constructed for every HSCT recipient, and use of available rooms is optional [CII].

Hospital rooms should have directed airflow so that air enters at one side of the room and is exhausted at the opposite side [BII]. Each hospital room should be well sealed (e.g., around windows and electrical outlets) [BII]. To provide consistent positive pressure in the HSCT recipient’s room, consistent pressure differentials should be maintained between patients’ rooms and the hallways or anterooms at \(>2.5\) Pascals [BII]. In general, air pressure in hospital rooms of HSCT recipients should be higher than in adjoining hallways, toilets, and anterooms.

Backup emergency power and redundant systems should be provided to maintain room pressurization and a constant number of air exchanges in HSCT units when the central ventilation system is shut off for maintenance and repair [BII]. In addition, protocols should be developed to protect HSCT units from bursts of mold spores when air-handling systems are restarted after routine maintenance [BIII].

**Construction**

Hospital construction and renovation have been associated with increased risk for nosocomial fungal infection, especially aspergillosis, among severely immunocompromised patients [BIV]. Therefore, people responsible for HSCT unit construction or renovation should consult published recommendations for environmental controls [BIII]. Planning for construction or renovation should include strategies for intensified aspergillosis-control measures [BIII]. The planning committee should include engineers, architects, infection control personnel, the director of the HSCT unit, administration representatives, and safety officers [BIII].

**Isolation**

HSCT units should follow published guidelines for hospital isolation practices, including CDC guidelines for the prevention of nosocomial infections [BII]. However, the efficacy of specific isolation and barrier precautions in preventing nosocomial infections in HSCT recipients has not been evaluated. HSCT recipients should be placed in private rooms [BIII]. When indicated, HSCT recipients should also be placed on airborne, droplet, or contact precautions in addition to standard precautions [BII]. Careful observation of isolation precautions is important to prevent transmission of infectious agents among HSCT recipients, health-care workers, and visitors.

**Hand Hygiene**

Hand hygiene is the single most effective procedure for preventing nosocomial infection [BIV]. Everyone, especially health-care workers, should wash hands before entering and after leaving rooms of HSCT recipients and candidates undergoing conditioning therapy (chemotherapy and radiation) [BIII] or before and after any direct contact with patients, regardless of whether hands were soiled [AII]. HSCT recipients should be encouraged to practice good hand hygiene (e.g., washing hands before eating, after using the toilet, before and after touching a wound) [BIII]. Hands should be washed with antimicrobial soap and water [AIII]; hygienic hand rubs are also an acceptable means of maintaining hand hygiene [BIII]. Health-care workers wearing gloves should put them on in the patient’s room after handwashing and then discard them in the same patient’s room before washing hands again on exiting the room. Gloves should always be changed between patients or before touching a clean area if the gloves become soiled (e.g., change gloves after touching the perineum and before touching a clean area) [AIII]. Appropriate gloves should be used by all persons handling potentially contaminated biological materials [AII].

**Equipment**

HSCT units should monitor opened and unopened wound-dressing supplies such as adhesive bandages [BIII] and surgical and elastic adhesive tape [BIII] to detect mold contamination and prevent cutaneous transmission to patients [BII]. All bandages and wound dressings should be discarded that are out of date, have damaged packaging, or are visually contaminated by construction debris, moisture. [BIII].

**Plants**

Exposure to plants and flowers has not been conclusively shown to cause fungal infections in HSCT recipients. However, most experts strongly recommend that plants and dried flower arrangements, fresh flowers [BIII]. HSCT units and clinics should follow published recommendations for washing and disinfecting toys [BIII].

**Play Areas and Toys**

Play areas for pediatric HSCT recipients and candidates undergoing conditioning therapy should be cleaned and disinfected weekly and as needed [BIII]. Only toys, games, and videos that can be kept clean and disinfected should be allowed in the HSCT unit [BIII]. HSCT units and clinics should follow published recommendations for washing and disinfecting toys [BIII].

**Health-Care Workers**

Each hospital or HSCT center should prepare a written comprehensive policy on the immunization of hospital personnel that meets current recommendations of CDC, the Advisory Committee on Immunization Practices, and the Healthcare Infection Control Practices Advisory Committee (26) [BIII]. Immunizations are needed to prevent transmission of vaccine-preventable diseases to HSCT recipients and candidates undergoing conditioning therapy. In general, health-care workers should be immune to measles, mumps, rubella, and especially varicella and influenza.

**Visitors**

Hospitals should have written policies for screening HSCT unit visitors, especially children, for potentially infectious conditions. Such screening should be performed by clinically trained health-care personnel [BIII]. Visitors who have communicable infectious diseases such as upper respiratory infection or flulike illness, recent exposure to communicable diseases, an active shingles rash (whether covered or not), a Varicella zoster-like rash within 6 weeks of receiving a chickenpox vaccine, or a history of receiving an oral polio vaccine within the previous 3 to 6 weeks should not
be allowed to enter the HSCT unit or have direct contact with HSCT recipients or candidates undergoing conditioning therapy [AII].

**Patient Skin Care**

Skin care during neutropenia should include daily inspection of sites likely to be portals of infection, such as the perineum and intravascular access sites [BIII]. HSCT recipients and candidates undergoing conditioning therapy should maintain good perineal hygiene to minimize loss of skin integrity and risk for infection [BIII]. To facilitate this, HSCT units should develop special protocols for patient perineal care. To prevent vaginal or cervical irritation and abrasions, menstruating immunosuppressed HSCT recipients should not use tampons [DIII]. (Immunosuppressed HSCT recipients are defined as being <24 months post-HSCT, on immunosuppressive therapy, or having graft-versus-host disease.) The use of rectal thermometers, enemas, suppositories, and rectal exams are contraindicated for HSCT recipients because of the risk for skin or mucosal breakdown [DIII].

**Oral and Dental Care**

Establishing optimal periodontal health before HSCT is one of the most important steps patients can take to avoid oral infections, and maintaining good oral hygiene after the transplant can minimize the severity and facilitate healing of mucositis, especially before engraftment [BIII]. All HSCT candidates should receive a dental evaluation and relevant treatment before conditioning therapy begins (27) [AIII]. Likely sources of dental infection should be rigorously eliminated [AIII].

HSCT recipients with mucositis and HSCT candidates undergoing conditioning therapy should maintain good oral hygiene by rinsing the mouth four to six times a day with sterile water, normal saline, or sodium bicarbonate solutions (27) [AIII]. HSCT recipients and candidates should brush their teeth at least twice a day with a soft regular toothbrush (27) [BIII]. Patients who cannot tolerate these brushings may use ultra-soft toothbrushes or sponge or foam toothettes (Sage Products, Crystal Lake, IL) [CIII], but these products are less effective in removing dental debris (17). Toothpaste is metronidazole, must be used judiciously (30) [AII]. Vancomycin and all other antibiotics, especially third-generation cephalosporins and anaerobic agents such as metronidazole, must be used judiciously (30) [AII].

**Specific Nosocomial Infections**

Nosocomial pathogens are potential threats to all patients; however, if infected, HSCT recipients are at risk for more severe disease. Nosocomial pathogens of concern include *Legionella* spp., methicillin-resistant *Staphylococcus aureus*, *Streptococcus viridans*, and *Mycobacterium tuberculosis*, and community respiratory viruses such as influenza, respiratory syncytial virus, adenovirus, and parainfluenza virus.

**Legionellosis**

Clinicians should always consider infection with *Legionella* spp. in the differential diagnosis of pneumonia in HSCT recipients. Because HSCT recipients are at much higher risk for disease and death from legionellosis (31), periodic routine culturing for legionellae in water samples from the transplant units’ potable water supply may be part of an overall prevention strategy in such units [CIII]. However, the optimal methods (frequency, number of sites) for environmental surveillance cultures in transplant units have not been determined, and the cost-effectiveness of this strategy has not been evaluated. Because HSCT recipients are at high risk for legionellosis and a safe concentration of legionellae organisms in potable water has not been determined, the goal, if environmental surveillance is undertaken, should be to maintain water systems with no detectable organisms [AIII]. Clinicians must maintain a high index of suspicion for legionellosis in transplant patients with nosocomial pneumonia even when environmental surveillance cultures do not yield legionellae [AIII].

**Community Respiratory Virus Infections**

Clinicians should institute appropriate precautions and infection control measures to prevent nosocomial pneumonia in hospitalized HSCT recipients and candidates undergoing conditioning therapy, especially during community or nosocomial respiratory virus outbreaks (5) [AIII]. Even when there is no nosocomial or community outbreak of respiratory virus infections, which are emerging infections in HSCT recipients, everyone who enters an HSCT unit, including visitors and health-care workers, should be screened daily for symptoms of upper respiratory infection [BIII]. Some experts recommend that health-care workers who work in HSCT units should provide daily verification (e.g., sign-in sheets) that they are symptom free before being allowed to care for patients. To minimize the risk for transmission, health-care workers and visitors with upper respiratory symptoms should be restricted from contact with HSCT recipients and candidates undergoing conditioning therapy [AIII]. All health-care workers with upper respiratory infection symptoms should be restricted from patient contact and reassigned to nonpatient care duties until their symptoms resolve [BIII]. Visitors with such symptoms should be asked to defer their visit to the HSCT unit until their symptoms resolve [BIII].
Viral shedding among HSCT recipients with community respiratory virus infection has been documented to last up to 4 months for influenza (32), 2 years for adenovirus (33), and 22 days for respiratory syncytial virus (34); however, viral shedding has been reported to last up to 112 days in a child with severe combined immunodeficiency (35). Therefore, to prevent nosocomial transmission, HSCT units should factor such possible prolonged viral shedding into policy decisions about duration of precautions for infected HSCT recipients or candidates undergoing conditioning therapy [CIII].

**Mycobacterium tuberculosis**

HSCT candidates should be screened for tuberculosis (TB) by a careful medical history and chart review to ascertain any history of TB exposure [AIII] because latent TB infection is more likely to progress to active disease among persons who are immunocompromised (36). HSCT units should also consider administering a tuberculin skin test (TST) by the Mantoux method with 5 tuberculin units of purified protein derivative (PPD) [CIII]; however, the TST may not be reliable in immunocompromised patients. Patients with a recent positive TST result or a history of a positive TST result and no prior preventive therapy should be given a chest X-ray and evaluated for active TB (36) [AI]. Because immunocompromised patients have a decreased ability to mount a delayed hypersensitivity response, a positive TST result for them is defined as >5 mm of induration (36) rather than ≥10 mm [CIII]. Since immunosuppressive therapy decreases the sensitivity of the TST, HSCT providers should not rely solely on the TST to determine presence of latent TB infection and need for preventive therapy [DIII]. Instead, a full 9-month course of isoniazid preventive therapy should be given to immunocompromised HSCT recipients or candidates who have had close contact with someone with active, infectious (i.e., sputum-smear positive) pulmonary or laryngeal TB, regardless of the HSCT recipient’s or candidate’s TST status (36) [BIII]. Routine anergy screening results may not be reliable for HSCT recipients and candidates undergoing conditioning therapy, and therefore such screening is not recommended [DIII]. HSCT should not be canceled or delayed because of a positive TST result [DIII].

**Infection Control Surveillance**

HSCT units should not perform routine fungal or bacterial cultures of asymptomatic HSCT recipients (37) [DII]. In the absence of epidemiologic clusters of infections, HSCT units should not perform routine periodic bacterial surveillance cultures of the HSCT unit environment or of equipment or devices used for respiratory therapy, pulmonary-function testing, or delivery of inhalation anesthesia (5) [DIII]. Some experts suggest that hospitals routinely sample air, ceiling tiles, ventilation ducts, and filters to test for molds, especially when construction or renovation occurs near or around the rooms of immunocompromised patients (24,37) or when clinical surveillance demonstrates a possible increase in mold (e.g., aspergillosis) cases [CIII]. In the absence of a nosocomial fungal outbreak, HSCT units need not perform routine fungal cultures of devices and dust in the rooms of HSCT recipients and candidates undergoing conditioning therapy [DIII]. HSCT units should routinely monitor the number of aspergillosis cases occurring in HSCT recipients, especially during hospital construction or renovation [BIII]. A twofold or greater increase in the attack rate of aspergillosis during any 6-month period indicates that the HSCT unit environment should be evaluated for breaks in infection control techniques and procedures and that the ventilation system should be carefully investigated (21) [BIII].

Careful adherence to the recommendations in these Guidelines for the Prevention of Opportunistic Infections in Hematopoietic Stem Cell Transplant Recipients may decrease the rate of hospital infections among HSCT recipients.

**Acknowledgments**


Dr. Dykewicz is a medical epidemiologist in the Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, CDC. She was an officer in the Epidemic Intelligence Service from 1989 to 1991 and completed a fellowship in pediatric infectious diseases at Yale University in 1995.

**References**


